Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring.

Wenningmann N, Knapp M, Ande A, Vaidya TR, Ait-Oudhia S.

Mol Pharmacol. 2019 Aug;96(2):219-232. doi: 10.1124/mol.119.115725. Epub 2019 Jun 4.

PMID:
31164387
2.

Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study.

Kim S, Sharma VD, Lingineni K, Farhan N, Fang L, Zhao L, Brown JD, Cristofoletti R, Vozmediano V, Ait-Oudhia S, Lesko LJ, Trame MN, Schmidt S.

J Clin Pharmacol. 2019 Sep;59(9):1266-1274. doi: 10.1002/jcph.1433. Epub 2019 May 14.

PMID:
31087554
3.

Combining Multiscale Experimental and Computational Systems Pharmacological Approaches to Overcome Resistance to HER2-targeted Therapy in Breast Cancer.

Vaidya TR, Ande A, Ait-Oudhia S.

J Pharmacol Exp Ther. 2019 Jun;369(3):531-545. doi: 10.1124/jpet.118.255752. Epub 2019 Mar 21.

PMID:
30898866
4.

Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities.

Chaar M, Kamta J, Ait-Oudhia S.

Onco Targets Ther. 2018 Sep 25;11:6227-6237. doi: 10.2147/OTT.S170138. eCollection 2018. Review.

5.

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer.

Franco YL, Vaidya TR, Ait-Oudhia S.

Breast Cancer (Dove Med Press). 2018 Sep 11;10:131-141. doi: 10.2147/BCTT.S170239. eCollection 2018. Review.

6.

Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer.

Ande A, Vaidya TR, Tran BN, Vicchiarelli M, Brown AN, Ait-Oudhia S.

Front Pharmacol. 2018 May 1;9:403. doi: 10.3389/fphar.2018.00403. eCollection 2018.

7.

Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma.

Ande A, Chaar M, Ait-Oudhia S.

J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):607-620. doi: 10.1007/s10928-018-9590-0. Epub 2018 May 3.

PMID:
29725796
8.

Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.

Vaidya T, Straubinger RM, Ait-Oudhia S.

Pharm Res. 2018 Mar 13;35(5):95. doi: 10.1007/s11095-018-2365-x.

PMID:
29536232
9.

Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors.

Vaidya T, Kamta J, Chaar M, Ande A, Ait-Oudhia S.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):401-418. doi: 10.1007/s10928-018-9578-9. Epub 2018 Feb 14.

PMID:
29446053
10.
11.

Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.

Fleisher B, Brown AN, Ait-Oudhia S.

Pharmacol Res. 2017 Oct;124:20-33. doi: 10.1016/j.phrs.2017.07.015. Epub 2017 Jul 19. Review.

PMID:
28735000
12.

A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates.

Ait-Oudhia S, Zhang W, Mager DE.

AAPS J. 2017 Sep;19(5):1436-1448. doi: 10.1208/s12248-017-0113-5. Epub 2017 Jun 23.

PMID:
28646408
13.

Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches.

Kamta J, Chaar M, Ande A, Altomare DA, Ait-Oudhia S.

Front Oncol. 2017 Apr 18;7:64. doi: 10.3389/fonc.2017.00064. eCollection 2017. Review.

14.

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy.

Robainas M, Otano R, Bueno S, Ait-Oudhia S.

Onco Targets Ther. 2017 Mar 23;10:1803-1807. doi: 10.2147/OTT.S132508. eCollection 2017. Review.

15.

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells.

Miao X, Koch G, Ait-Oudhia S, Straubinger RM, Jusko WJ.

Front Pharmacol. 2016 Nov 15;7:421. eCollection 2016.

16.

Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.

Ait-Oudhia S, Ovacik MA, Mager DE.

MAbs. 2017 Jan;9(1):15-28. doi: 10.1080/19420862.2016.1238995. Epub 2016 Sep 23. Review.

17.

Current advances in biomarkers for targeted therapy in triple-negative breast cancer.

Fleisher B, Clarke C, Ait-Oudhia S.

Breast Cancer (Dove Med Press). 2016 Oct 6;8:183-197. eCollection 2016. Review.

18.

Array of translational systems pharmacodynamic models of anti-cancer drugs.

Ait-Oudhia S, Mager DE.

J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):549-565. Epub 2016 Oct 22. Review.

PMID:
27771815
19.

Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.

Ait-Oudhia S, Mager DE, Pokuri V, Tomaszewski G, Groman A, Zagst P, Fetterly G, Iyer R.

CPT Pharmacometrics Syst Pharmacol. 2016 Jun;5(6):297-304. doi: 10.1002/psp4.12084. Epub 2016 Jun 8.

20.

Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial.

Pokuri VK, Tomaszewski GM, Ait-Oudhia S, Groman A, Khushalani NI, Lugade AA, Thanavala Y, Ashton EA, Grande C, Fetterly GJ, Iyer R.

Am J Clin Oncol. 2018 Apr;41(4):332-338. doi: 10.1097/COC.0000000000000286.

PMID:
27014931
21.

Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis.

Grimsrud KN, Ait-Oudhia S, Durbin-Johnson BP, Rocke DM, Mama KR, Rezende ML, Stanley SD, Jusko WJ.

J Vet Pharmacol Ther. 2015 Feb;38(1):24-34. doi: 10.1111/jvp.12139. Epub 2014 Jul 29.

22.

Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.

Ait-Oudhia S, Mager DE, Straubinger RM.

Pharmaceutics. 2014 Mar 18;6(1):137-74. doi: 10.3390/pharmaceutics6010137.

23.

Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan.

Liu ZJ, Hoffmeister KM, Hu Z, Mager DE, Ait-Oudhia S, Debrincat MA, Pleines I, Josefsson EC, Kile BT, Italiano J Jr, Ramsey H, Grozovsky R, Veng-Pedersen P, Chavda C, Sola-Visner M.

Blood. 2014 May 29;123(22):3381-9. doi: 10.1182/blood-2013-06-508200. Epub 2014 Mar 5.

24.

A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity.

Perera V, Gross AS, Forrest A, Landersdorfer CB, Xu H, Ait-Oudhia S, McLachlan AJ.

Drug Metab Dispos. 2013 Nov;41(11):1957-66. doi: 10.1124/dmd.113.053074. Epub 2013 Aug 30.

PMID:
23996078
25.

AMGET, an R-Based Postprocessing Tool for ADAPT 5.

Guiastrennec B, Wollenberg L, Forrest A, Ait-Oudhia S.

CPT Pharmacometrics Syst Pharmacol. 2013 Jul 31;2:e61. doi: 10.1038/psp.2013.36.

26.

Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness.

Yan X, Ait-Oudhia S, Krzyzanski W.

Pharm Res. 2013 Apr;30(4):1026-36. doi: 10.1007/s11095-012-0938-7. Epub 2012 Nov 28.

27.

Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy.

Ait-Oudhia S, Straubinger RM, Mager DE.

J Pharmacol Exp Ther. 2013 Jan;344(1):103-12. doi: 10.1124/jpet.112.199109. Epub 2012 Oct 31. Erratum in: J Pharmacol Exp Ther. 2018 Aug;366(2):365-366.

28.

Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.

Ait-Oudhia S, Straubinger RM, Mager DE.

Pharm Res. 2012 Oct;29(10):2833-44. doi: 10.1007/s11095-012-0775-8. Epub 2012 May 17.

PMID:
22588463
29.

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics.

Ait-Oudhia S, Lowe PJ, Mager DE.

CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1:e5. doi: 10.1038/psp.2012.6.

30.

Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients.

Ait-Oudhia S, Vermeulen A, Krzyzanski W.

Biopharm Drug Dispos. 2011 Jan;32(1):1-15. doi: 10.1002/bdd.733. Epub 2010 Dec 7.

PMID:
21162115
31.

Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats.

Ait-Oudhia S, Scherrmann JM, Krzyzanski W.

Biopharm Drug Dispos. 2010 Jul;31(5-6):298-315. doi: 10.1002/bdd.712.

PMID:
20578212
32.

Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.

Ait-Oudhia S, Scherrmann JM, Krzyzanski W.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):897-910. doi: 10.1124/jpet.110.167304. Epub 2010 May 25.

33.

Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats.

Wiczling P, Ait-Oudhia S, Krzyzanski W.

Cytometry A. 2009 Jul;75(7):584-92. doi: 10.1002/cyto.a.20736.

Supplemental Content

Loading ...
Support Center